urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

BMS presses go on Nektar combo pivotal trials, despite data debate

The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... Nektar and BMS also reported initial stage 1 data in

Latest news

Keytruda gains NICE clearance in first line bladder cancer

Cost effectiveness watchdog NICE issued a Final Appraisal Determination (FAD) on Friday, recommending MSD’s treatment within the cancer drugs fund (CDF) for untreated locally advanced or metastatic urothelial carcinoma in ... Pembrolizumab is already
Another Tecentriq win for Roche as Avastin combo boosts survival

Tecentriq is currently approved for previously-treated NSCLC patients and also as a second-line therapy for metastatic urothelial carcinoma, a form of bladder cancer.
NICE says OK to Keytruda for bladder cancer via the CDF

metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. ... Louise Houson, UK managing director for MSD, said: “MSD is really pleased that NICE has recommended pembrolizumab for eligible patients with advanced
MSD’s Keytruda wins bladder cancer indication in Japan

The pharma giant ’s blockbuster has gained a new indication to treat patients with previously treated urothelial carcinoma (UC) that is unresectable with radical surgery and whose disease has progressed following ... chemotherapy. Dr Roy Baynes,
Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

The drug is already approved as a treatment for rare cancer Merkel cell carcinoma and as a second-line therapy for bladder cancer (metastatic urothelial carcinoma), but Pfizer and Merck are

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Director: Excellent benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer: Great salary and benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Scientific Director / Editorial Team Leader: Great salary and benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Project / Account Manager (Medical Education): Salary TBC

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Director development role to Business Director, H...: Excellent package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Medical Writer: Competitive Salary

Director, Market Access / HEOR - North-West: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Manager / Account Director: Competative

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Events Manager – Med Comms – Surrey: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Medical Writers Required – Cheshire: DOE

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...